Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-HER2 CAR-T in HER2 Positive Cancer
NCT02713984Phase 2Withdrawn
- Start
- Mar 2016
- Primary completion
- Jul 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Anti-HER2 CAR-T Cell Injection in breast cancer, ovarian cancer, lung cancer, gastric cancer (GC), colorectal cancer (CRC). Planned start Mar 2016; status: withdrawn.
02
Drugs
Anti-HER2 CAR-T Cell Injection
03
Conditions
breast cancerovarian cancerlung cancergastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02713984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02713984.